Daxor's BVA-100 diagnostic blood test shortens the length of hospital stay for patients with heart failure

Daxor's BVA-100 diagnostic blood test shortens the length of hospital stay for patients with heart failure

Daxor Corporation, the global leader in blood volume measurement technology, today announces new data confirming the benefits of the company's BVA-100 diagnostic blood test in reducing length of hospital stay (LOS) for patients with heart failure (HF). The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022, which brought together the world's leading heart failure experts in Washington, DC, September 30-October 3, 2022.

"This important study shows that BVA can help clinicians treat patients more effectively, allowing them to leave the hospital more quickly and achieve better mortality and readmission outcomes than those who did not receive BVA-guided care. Annual heart failure treatment costs are estimated at $30.7 billion and are expected to reach nearly $70 billion by 2030 will increase if we do not improve current patient outcomes," said Michael Feldschuh, CEO and President of Daxor Corporation.

A shorter length of hospital stay has enormous potential for hospital cost savings, as hospitals receive a one-time block payment in accordance with the DRG reimbursement rules. All hospital systems are evaluated on this metric, and finding ways to improve is one of the reasons we adopted BVA locally.”

Dr. John L. Jefferies, University of Tennessee Health Sciences Center, Memphis, TN

We are pleased to announce that Daxor once again had a strong presence at this year's HFSA," said Jonathan Feldschuh, Chief Scientific Officer of Daxor Corporation. "The clinical evidence continues to demonstrate that our innovative BVA-100 blood test uniquely enables physicians to understand heart failure's underlying blood volume abnormalities by providing them with accurate, “Provide actionable data to individualize treatment plans in both inpatient and outpatient settings – improving outcomes and reducing overall costs of care.”

The study, titled “Length of Stay After Blood Volume Analysis in Hospitalized Heart Failure,” compared both hospital admission and discharge data and allowed LOS to be calculated before and after BVA for all patients. Those who received BVA-guided treatment on the day of hospital admission had a highly significantly (p < 0.001) lower overall LOS than the control group (2.04 vs. 4.56 days) and significantly improved outcomes (lower 30-day and 365-day readmissions). Mortality).

Source:

Daxor Corporation

.